Mirum Pharmaceuticals (MIRM) stock is in focus after the company and Incyte reported pivotal Phase 2 data for zilurgisertib in fibrodysplasia ossificans progressiva, alongside FDA Priority Review of its New Drug Application.

At a share price of $107.13, Mirum Pharmaceuticals has seen strong recent momentum, with a 30 day share price return of 8.63% and a year to date share price return of 37.22%. The 1 year total shareholder return of 113.09% and 3 year total shareholder return above 3x highlight how sentiment around its rare disease portfolio has shifted.

If progress on rare disease programs like zilurgisertib has your attention, it can be useful to see what else is moving in specialized healthcare, starting with 38 healthcare AI stocks

With Mirum Pharmaceuticals trading at $107.13 alongside strong recent returns and an intrinsic value estimate that signals a sizable gap, investors have to ask whether this is still an underappreciated rare disease story or if the market is already pricing in future growth.

Most Popular Narrative: 26% Undervalued

With Mirum Pharmaceuticals closing at $107.13 versus a narrative fair value of $144.15, the current analyst consensus is framing a sizable valuation gap built on a specific growth and profitability path.

Multiple late-stage pipeline catalysts, including three pivotal study readouts (VISTAS, VANTAGE, EXPAND) over the next 24 months and the initiation of the Phase II Fragile X study, set the stage for further product label expansions and new indication launches, underpinning future revenue diversification and potential earnings acceleration.

Want to see what is sitting underneath that optimism for Mirum Pharmaceuticals? Revenue compounding, margin swing, and a future earnings profile that looks very different to today. Curious which assumptions have to hold for that to line up with a $144.15 fair value?

Result: Fair Value of $144.15 (UNDERVALUED)

However, Mirum Pharmaceuticals still carries key risks, including its heavy reliance on LIVMARLI, and the possibility that rivals or pricing pressure could challenge future revenue expectations.

Next Steps

Reading all this optimism and caution around Mirum Pharmaceuticals, do you want to rely on others or weigh the trade off yourself while sentiment is fresh? Take a closer look at the underlying risks and upside catalysts through the 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond Mirum Pharmaceuticals?

If Mirum Pharmaceuticals has sharpened your focus on opportunities in healthcare, do not stop here. Broaden your watchlist with other high conviction ideas using targeted screeners.

• Target powerful potential re-ratings by scanning companies that screen well on value using the 44 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks with robust yields and resilience through the 7 dividend fortresses.
• Prioritize resilience by checking companies that show sturdy balance sheets and fundamentals via the solid balance sheet and fundamentals stocks screener (48 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.